CANSINOBIO (06185) A-share trading abnormal fluctuation; no material information that should be disclosed but has not been disclosed

CANSINOBIO (06185) has issued an announcement that the cumulative deviation of the closing price of the Company's shares exceeded 30% over three consecutive trading days on September 28, September 29, and September 30, 2026. According to the relevant provisions of the Shanghai Stock Exchange Trading Rules and the Shanghai Stock Exchange Rules for Real-time Monitoring of Abnormal Trading of Stocks on the Science and Technology Innovation Board, this constitutes an abnormal fluctuation of stock trading. Following the Company's self-examination, the Company's current production and operating activities are normal, and its internal operating order is normal. No major adjustments have occurred in the market environment or industry policies in which the Company operates. Following the Company's self-examination and verification by sending letters to the Company's controlling shareholder and actual controller, as of the disclosure date of this announcement, the Company's controlling shareholder and actual controller do not have any major matters that should be disclosed but have not been disclosed, other than information already publicly disclosed on designated information disclosure media, including but not limited to major matters currently being planned such as mergers and acquisitions, share issuance, debt restructuring, business restructuring, asset divestiture, and asset injection. The Company has noted recent market attention to the development of mRNA technology, and the release or planned public disclosure of phased clinical data for overseas mRNA tumor vaccines. The mRNA platform is one of the technology platforms in which the Company has invested. The Company is conducting the development of mRNA preventive vaccines and therapeutic biological products, as well as the development of related delivery systems. In terms of therapeutic areas, the Company is advancing research and development work on mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, all of which are currently at an early stage. Upon verification, the Company has not found any other major events that may have a significant impact on the Company's stock price. During the period of this abnormal fluctuation of the Company's stock trading, none of the Company's directors, senior management personnel, controlling shareholder, or its persons acting in concert have bought or sold the Company's shares.